177 related articles for article (PubMed ID: 21063134)
1. Treatment efficacy/safety and prognostic factors in patients with advanced biliary tract cancer receiving gemcitabine monotherapy: an analysis of 100 cases.
Suzuki E; Furuse J; Ikeda M; Okusaka T; Nakachi K; Mitsunaga S; Ueno H; Morizane C; Kondo S; Shimizu S; Kojima Y; Hagihara A
Oncology; 2010; 79(1-2):39-45. PubMed ID: 21063134
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of gemcitabine monotherapy for patients with advanced biliary tract cancer.
Yokoyama T; Yoshida H; Makino H; Maruyama H; Suzuki S; Matsutani T; Matsushita A; Hirakata A; Sasajima K; Uchida E
J Nippon Med Sch; 2012; 79(3):204-12. PubMed ID: 22791122
[TBL] [Abstract][Full Text] [Related]
3. Gemcitabine-based chemotherapy for advanced biliary tract carcinomas.
Abdel-Rahman O; Elsayed Z; Elhalawani H
Cochrane Database Syst Rev; 2018 Apr; 4(4):CD011746. PubMed ID: 29624208
[TBL] [Abstract][Full Text] [Related]
4. A retrospective study of S-1 monotherapy as second-line treatment for patients with advanced biliary tract cancer.
Kobayashi S; Ueno M; Ohkawa S; Andou T; Kameda R; Yamamoto N; Morinaga S
Jpn J Clin Oncol; 2012 Sep; 42(9):800-6. PubMed ID: 22826349
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and biomarker analysis of nivolumab plus gemcitabine and cisplatin in patients with unresectable or metastatic biliary tract cancers: results from a phase II study.
Feng K; Liu Y; Zhao Y; Yang Q; Dong L; Liu J; Li X; Zhao Z; Mei Q; Han W
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32487569
[TBL] [Abstract][Full Text] [Related]
6. Multicenter phase II study of S-1 monotherapy as second-line chemotherapy for advanced biliary tract cancer refractory to gemcitabine.
Sasaki T; Isayama H; Nakai Y; Mizuno S; Yamamoto K; Yagioka H; Yashima Y; Kawakubo K; Kogure H; Togawa O; Matsubara S; Ito Y; Sasahira N; Hirano K; Tsujino T; Toda N; Tada M; Omata M; Koike K
Invest New Drugs; 2012 Apr; 30(2):708-13. PubMed ID: 20924641
[TBL] [Abstract][Full Text] [Related]
7. Phase II study of single-agent gemcitabine in patients with advanced biliary tract cancer.
Okusaka T; Ishii H; Funakoshi A; Yamao K; Ohkawa S; Saito S; Saito H; Tsuyuguchi T
Cancer Chemother Pharmacol; 2006 May; 57(5):647-53. PubMed ID: 16142487
[TBL] [Abstract][Full Text] [Related]
8. Single-agent gemcitabine in the treatment of advanced biliary tract cancers: a phase II study.
Park JS; Oh SY; Kim SH; Kwon HC; Kim JS; Jin-Kim H; Kim YH
Jpn J Clin Oncol; 2005 Feb; 35(2):68-73. PubMed ID: 15709089
[TBL] [Abstract][Full Text] [Related]
9. A retrospective study of chemotherapy with cisplatin plus gemcitabine after the failure of gemcitabine monotherapy for biliary tract cancer.
Kameda R; Ando T; Kobayashi S; Ueno M; Ohkawa S
Jpn J Clin Oncol; 2013 Jun; 43(6):636-40. PubMed ID: 23619988
[TBL] [Abstract][Full Text] [Related]
10. A multicenter phase II study of S-1 for gemcitabine-refractory biliary tract cancer.
Suzuki E; Ikeda M; Okusaka T; Nakamori S; Ohkawa S; Nagakawa T; Boku N; Yanagimoto H; Sato T; Furuse J
Cancer Chemother Pharmacol; 2013 May; 71(5):1141-6. PubMed ID: 23525694
[TBL] [Abstract][Full Text] [Related]
11. Single-agent gemcitabine in elderly patients with unresectable biliary tract cancer.
Kuriyama H; Kawana K; Taniguchi R; Jono F; Sakai E; Okubo H; Suzuki H; Kobayashi S; Murata Y; Inamori M; Hata Y; Nakajima A
Hepatogastroenterology; 2011; 58(105):26-30. PubMed ID: 21510281
[TBL] [Abstract][Full Text] [Related]
12. Liposomal irinotecan plus fluorouracil and leucovorin versus fluorouracil and leucovorin for metastatic biliary tract cancer after progression on gemcitabine plus cisplatin (NIFTY): a multicentre, open-label, randomised, phase 2b study.
Yoo C; Kim KP; Jeong JH; Kim I; Kang MJ; Cheon J; Kang BW; Ryu H; Lee JS; Kim KW; Abou-Alfa GK; Ryoo BY
Lancet Oncol; 2021 Nov; 22(11):1560-1572. PubMed ID: 34656226
[TBL] [Abstract][Full Text] [Related]
13. Phase II trial of two-weekly gemcitabine in patients with advanced biliary tract cancer.
Penz M; Kornek GV; Raderer M; Ulrich-Pur H; Fiebiger W; Lenauer A; Depisch D; Krauss G; Schneeweiss B; Scheithauer W
Ann Oncol; 2001 Feb; 12(2):183-6. PubMed ID: 11300321
[TBL] [Abstract][Full Text] [Related]
14. Prognostic predictive values of gemcitabine sensitivity-related gene products for unresectable or recurrent biliary tract cancer treated with gemcitabine alone.
Murata A; Amano R; Yamada N; Kimura K; Yashiro M; Nakata B; Hirakawa K
World J Surg Oncol; 2013 May; 11():117. PubMed ID: 23710668
[TBL] [Abstract][Full Text] [Related]
15. Safety and effectiveness of gemcitabine in 260 patients with biliary tract cancer in a Japanese clinical practice based on post-marketing surveillance in Japan.
Okubo S; Nishiuma S; Kobayashi N; Taketsuna M; Taniai H
Jpn J Clin Oncol; 2012 Nov; 42(11):1043-53. PubMed ID: 23042772
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of gemcitabine-based chemotherapies in biliary tract cancer: a meta-analysis.
Liu H; Zhang QD; Li ZH; Zhang QQ; Lu LG
World J Gastroenterol; 2014 Dec; 20(47):18001-12. PubMed ID: 25548500
[TBL] [Abstract][Full Text] [Related]
17. Predictive factors of the treatment outcome in patients with advanced biliary tract cancer receiving gemcitabine plus cisplatin as first-line chemotherapy.
Suzuki Y; Kan M; Kimura G; Umemoto K; Watanabe K; Sasaki M; Takahashi H; Hashimoto Y; Imaoka H; Ohno I; Mitsunaga S; Ikeda M
J Gastroenterol; 2019 Mar; 54(3):281-290. PubMed ID: 30298469
[TBL] [Abstract][Full Text] [Related]
18. Single-agent gemcitabine in elderly patients with unresectable biliary tract cancer.
Kuriyama H; Kawana K; Taniguchi R; Jono F; Sakai E; Ohubo H; Suzuki H; Kobayashi S; Murata Y; Inamori M; Hata Y; Nahajima A
Hepatogastroenterology; 2011; 58(106):270-4. PubMed ID: 21661380
[TBL] [Abstract][Full Text] [Related]
19. Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study.
Lee J; Park SH; Chang HM; Kim JS; Choi HJ; Lee MA; Jang JS; Jeung HC; Kang JH; Lee HW; Shin DB; Kang HJ; Sun JM; Park JO; Park YS; Kang WK; Lim HY
Lancet Oncol; 2012 Feb; 13(2):181-8. PubMed ID: 22192731
[TBL] [Abstract][Full Text] [Related]
20. PICCA study: panitumumab in combination with cisplatin/gemcitabine chemotherapy in KRAS wild-type patients with biliary cancer-a randomised biomarker-driven clinical phase II AIO study.
Vogel A; Kasper S; Bitzer M; Block A; Sinn M; Schulze-Bergkamen H; Moehler M; Pfarr N; Endris V; Goeppert B; Merx K; Schnoy E; Siveke JT; Michl P; Waldschmidt D; Kuhlmann J; Geissler M; Kahl C; Evenkamp R; Schmidt T; Kuhlmann A; Weichert W; Kubicka S
Eur J Cancer; 2018 Mar; 92():11-19. PubMed ID: 29413685
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
